Another cancer-related biotech in my portfolio, in addition to Northwest Bio and Cel-Sci, is a company out of Finland called Faron Pharmaceuticals.
It's still rather early stage, but information coming out from studies on their "Clevegen" product look very encouraging. I think this is one to keep an eye on going forward.
From today's new release:
"TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces an update from its ongoing bexmarilimab MATINS study, indicating significant efficacy signals among a number of patients in Part II of the trial, alongside a recommendation from the study's data monitoring committee (DMC) to increase the dosing frequency in all cohorts showing early clinical benefits."
"Dr. Markku Jalkanen, Faron's CEO, said: "This is very exciting data supporting bexmarilimab's unique mechanism of action and adding to the accumulating evidence of bexmarilimab's broad potential across a range of hard-to-treat cancers. The early observations of survival benefit and the stark contrast in progression of disease among patients who do not respond to bexmarilimab therapy show the clinical significance of Clever-1 as immunotherapy target and the potential patient benefit when its immune-suppressive control is removed. We look forward to gathering further data from these patient cohorts to support the design of our pivotal trials for bexmarilimab.""
https://otp.tools.investis.com/clients/uk/faron/rns/regulatory-story.aspx?newsid=1462608&cid=2223
jmo
